Mr. Harry F. Arader, MBA is the Chief Executive Officer of Companion Pharma, Inc. Mr. Arader served as a Senior Entrepreneurial Advisor of BioGenerator, since September 2011. He serves as the Chief Executive Officer at Midway Food Animal Sciences and was earlier Acting Chief Executive Officer. He co-founded Nanodisc, Inc. in 2003 and serves as its Vice President of Bus Operations. He serves as Business Development Consultant to Orion Genomics LLC. He has recently taken on the role of Chief Executive Officer of Apse LLC. In addition, he acts as Senior Business Mentor companies including KyPha, Inc. and others. At BioGenerator, Mr. Arader creates and manages new life-science companies that have received or are strong candidates for firm’s funding. He has 29 years of life science commercialization experience. Mr. Arader was Founder and President of The Centromere Group. Along with providing consulting services to a wide range of lifescience clients through the Centromere Group, he devoted time to start-up companies. He served as Chief Business Officer and Interim President at Nanodisc Inc. from 2003 to 2007. Since 1998, Mr. Arader served as Chief Business Officer of Orion Genomics LLC. He served as an Executive Director of Strategic Planning at Searle Pharmaceuticals from 1990 to 1992. He also served as Chief Executive Officer for BioDisplay Technologies Inc. Since 1998, he served as a Senior Business Advisor to Unimed Pharmaceuticals. Mr. Arader founded Centromere Group and served as its President. In economic development projects at the Centromere Group, from 1997 to 1998, he wrote the “Illinois State Strategic Plan for the Biotechnology Industry“. Based on the warm reception for the recommendations in this study, in 1998 he served on the transition team for former Illinois Governor George Ryan. He was one of the founders of IBIO (the Illinois Biotechnology Industry Organization) and launched the successful effort that resulted in adapting the BIO 2006 trade-show. Mr. Arader was also the Principle Consultant to the University of Illinois during the design of Illinois Ventures. From 1996 to 1997, he served as Chief Financial Officer of Millennium Pharmaceuticals Inc. He was also a key driver of the acquisition of Chemgenics Pharmaceuticals. He built and led the Finance, Strategic Planning, Investor Relations, Materials Management and Facilities functions during a period of rapid company growth. Prior to Millennium, he spent 10 years at Searle. He served as Managing Director of Searle Greater China from 1993 to 1996, he held full P&L responsibility for all company operations there. Some of his specific projects included the creation of a sales and marketing organization on the Chinese mainland, the negotiation of joint ventures with two Chinese companies and the streamlining of operations. He served as Vice President of International Marketing at Searle Pharmaceuticals from 1992 to 1993. Mr. Arader had extensive experiences in Europe and Asia. Among many other projects, he was instrumental in a co-promotion agreement for the launch of Searle's Arthrotec brand in Germany, which resulted in a 75% improvement in market share versus projections. He was also extensively involved in Searle's Japan operations, leading a product repositioning effort and the reorganization of the sales and marketing functions yielding a $70 million improvement in operating earnings. Mr. Arader was also a leader in Searle's successful public policy efforts that led to the elevation of Chairman Gilgore to the head of the industry trade association, PhRMA where he played an important role in dealing with the planned Clinton Health Plan. In his early days at Searle he focused on marketing and business development. As Product Director – GI/Anti-inflammatory Products, he developed and implemented the launch plan for Cytotec, the innovative product for the prevention of ulcers associated with arthritis medications. As Associate Director of New Products, US, he led the efforts to in-license the Daypro and Ambien brands that went on to became Searle's number one and two revenue generators through most of the 1990s. Prior to joining Searle, he served Sales and Marketing positions at Merck & Co. As Marketing Research Analyst, Mr. Arader built on his Pharmaceutical Sales Representative experiences as he headed up a team that developed the industry's first rigorously controlled promotion productivity testing capability. In early 2013, Mr. Arader created MetaCROM Services LLC where he serves as the Managing Member and Chairman of the Board. He serves as a Director at BioGenerator. Since 2005, he has been an Independent Director of Midway Pharmaceuticals Inc. He served as Director of Nanodisc, Inc. Mr. Arader joined the board of the Ox-Bow. Mr. Arader earned an M.B.A. in Marketing and Strategic Planning from the Wharton School in 1983 and a B.A. in Cultural Anthropology from the State University of New York at Purchase in 1976. Mr. Harry F. Arader, MBA is the Chief Executive Officer of Companion Pharma, Inc. Mr. Arader served as a Senior Entrepreneurial Advisor of BioGenerator, since September 2011. He serves as the Chief Executive Officer at Midway Food Animal Sciences and was earlier Acting Chief Executive Officer. He co-founded Nanodisc, Inc. in 2003 and serves as its Vice President of Bus Operations. He serves as Business Development Consultant to Orion Genomics LLC. He has recently taken on the role of Chief Executive Officer of Apse LLC. In addition, he acts as Senior Business Mentor companies including KyPha, Inc. and others. At BioGenerator, Mr. Arader creates and manages new life-science companies that have received or are strong candidates for firm’s funding. He has 29 years of life science commercialization experience. Mr. Arader was Founder and President of The Centromere Group. Along with providing consulting services to a wide range of lifescience clients through the Centromere Group, he devoted time to start-up companies. He served as Chief Business Officer and Interim President at Nanodisc Inc. from 2003 to 2007. Since 1998, Mr. Arader served as Chief Business Officer of Orion Genomics LLC. He served as an Executive Director of Strategic Planning at Searle Pharmaceuticals from 1990 to 1992. He also served as Chief Executive Officer for BioDisplay Technologies Inc. Since 1998, he served as a Senior Business Advisor to Unimed Pharmaceuticals. Mr. Arader founded Centromere Group and served as its President. In economic development projects at the Centromere Group, from 1997 to 1998, he wrote the “Illinois State Strategic Plan for the Biotechnology Industry“. Based on the warm reception for the recommendations in this study, in 1998 he served on the transition team for former Illinois Governor George Ryan. He was one of the founders of IBIO (the Illinois Biotechnology Industry Organization) and launched the successful effort that resulted in adapting the BIO 2006 trade-show. Mr. Arader was also the Principle Consultant to the University of Illinois during the design of Illinois Ventures. From 1996 to 1997, he served as Chief Financial Officer of Millennium Pharmaceuticals Inc. He was also a key driver of the acquisition of Chemgenics Pharmaceuticals. He built and led the Finance, Strategic Planning, Investor Relations, Materials Management and Facilities functions during a period of rapid company growth. Prior to Millennium, he spent 10 years at Searle. He served as Managing Director of Searle Greater China from 1993 to 1996, he held full P&L responsibility for all company operations there. Some of his specific projects included the creation of a sales and marketing organization on the Chinese mainland, the negotiation of joint ventures with two Chinese companies and the streamlining of operations. He served as Vice President of International Marketing at Searle Pharmaceuticals from 1992 to 1993. Mr. Arader had extensive experiences in Europe and Asia. Among many other projects, he was instrumental in a co-promotion agreement for the launch of Searle's Arthrotec brand in Germany, which resulted in a 75% improvement in market share versus projections. He was also extensively involved in Searle's Japan operations, leading a product repositioning effort and the reorganization of the sales and marketing functions yielding a $70 million improvement in operating earnings. Mr. Arader was also a leader in Searle's successful public policy efforts that led to the elevation of Chairman Gilgore to the head of the industry trade association, PhRMA where he played an important role in dealing with the planned Clinton Health Plan. In his early days at Searle he focused on marketing and business development. As Product Director – GI/Anti-inflammatory Products, he developed and implemented the launch plan for Cytotec, the innovative product for the prevention of ulcers associated with arthritis medications. As Associate Director of New Products, US, he led the efforts to in-license the Daypro and Ambien brands that went on to became Searle's number one and two revenue generators through most of the 1990s. Prior to joining Searle, he served Sales and Marketing positions at Merck & Co. As Marketing Research Analyst, Mr. Arader built on his Pharmaceutical Sales Representative experiences as he headed up a team that developed the industry's first rigorously controlled promotion productivity testing capability. In early 2013, Mr. Arader created MetaCROM Services LLC where he serves as the Managing Member and Chairman of the Board. He serves as a Director at BioGenerator. Since 2005, he has been an Independent Director of Midway Pharmaceuticals Inc. He served as Director of Nanodisc, Inc. Mr. Arader joined the board of the Ox-Bow. Mr. Arader earned an M.B.A. in Marketing and Strategic Planning from the Wharton School in 1983 and a B.A. in Cultural Anthropology from the State University of New York at Purchase in 1976.

Veterinary Science & Medical Diagnosis